Keywords: genentech, idec, seek, broaden, nhl, indications, rituxan

Genentech and IDEC seek to broaden NHL indications for Rituxan

Article | 08 December 1999

Print This

Genentech and IDEC are to start a Phase III trial in January 2000 oftheir anti-CD20 antibody Rituxan (rituximab), in combination with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in